Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Vistagen Therapeutics Inc (VTGN)

Vistagen Therapeutics Inc (VTGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Vistagen Therapeutics Inc 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 USA

www.vistagen.com P: 650-577-3600 F: 888-482-2602

Description:

VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder. VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.

Key Statistics

Overview:

Market Capitalization, $K 129,179
Enterprise Value, $K 112,539
Shares Outstanding, K 27,025
Annual Sales, $ -230 K
Annual Net Income, $ -59,250 K
Last Quarter Sales, $ 410 K
Last Quarter Net Income, $ -6,350 K
EBIT, $ -33,900 K
EBITDA, $ -33,770 K
60-Month Beta 0.77
% of Insider Shareholders 0.96%
% of Institutional Shareholders 78.39%
Float, K 26,766
% Float 99.04%
Short Volume Ratio 0.47

Growth:

1-Year Return 10.49%
3-Year Return -93.70%
5-Year Return -71.39%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 74.47%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.22 on 02/13/24
Latest Earnings Date N/A
Earnings Per Share ttm -1.82
EPS Growth vs. Prev Qtr 66.67%
EPS Growth vs. Prev Year 85.35%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-30 on 06/07/23

VTGN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -72.10%
Return-on-Assets % -61.24%
Profit Margin % 25,760.87%
Debt/Equity 0.00
Price/Sales 61.98
Price/Cash Flow N/A
Price/Book 1.03
Book Value/Share 4.56
Interest Coverage -3.04
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar